Gilead Sciences reported $2.3 billion in sales of Sovaldi, a new hepatitis C drug that has raised an outcry over its $1,000-a-pill price.
via NYT > Health http://ift.tt/1nnuJ7v
via All Health and Fitness http://ift.tt/1kZoFzp
Gilead Sciences reported $2.3 billion in sales of Sovaldi, a new hepatitis C drug that has raised an outcry over its $1,000-a-pill price.
via NYT > Health http://ift.tt/1nnuJ7v
No comments:
Post a Comment